Jubilant revenue up 52% in Q2
Jubilant Organosys, one of the largest custom research and manufacturing services and drug discovery and development services company, recorded a revenue growth of 52.1 pc for the second quarter, reports HT Correspondent.business Updated: Oct 14, 2008 21:47 IST
Jubilant Organosys, one of the largest custom research and manufacturing services (CRAMS) and drug discovery and development services company, recorded a revenue growth of 52.1 per cent to Rs. 940.5 crore for the second quarter ended on September 30, 2008.
International revenue of the company also grew by 64.8 per cent at Rs. 537.2 crore. The company received revenue worth 55.4 per cent and 14.2 per cent from North America and European Union with a growth of 95.9 per cent and 32.7 per cent respectively.
The consolidated EBITDA (earnings before interest, taxes, depreciation and amortization) in the quarter grew by 56.2 per cent and stood at Rs. 184.3 crore.
The net profit before exceptional item stood at Rs. 111.5 crore, a growth of 35.6 per cent and diluted EPS (earnings per share) for the period was at Rs. 6.24 against Rs. 4.61 during the same period last year.
The revenue of the company rose by 52.5 per cent to Rs. 1,767.1 crore for first half ended September 30, 2008 over the same period last year. The international revenue has increased by 68.9 per cent at Rs. 1,021.8 crore on account of good growth across all segments.
Consolidated EBITDA this half yearly has jumped by 64.4 per cent totaling Rs 355.2 crore. Net Profit before exceptional items stood at Rs 231.9 crore, a growth of 69.0 per cent and diluted EPS for the period was thus at Rs 12.97 against Rs 7.69 in in the first half of the current financial year.
“Jubilant has consistently delivered robust performance on the back of its strong business model focussing on CRAMS and drug discovery and development services,” said Shyam S Bhartia, chairman and managing director and Hari S Bhartia, co-chairman and managing director, Jubilant Organosys Ltd.
“We are strengthening Jubilant’s position as a leading outsourcing partner by offering a complete suite of products and services in pharma value chain, which will help us deliver incremental growth,” they added.